All Stories

Fierce Pharma Asia—Former China FDA head under investigation; Daiichi pulls ADC filing

China's anti-graft watchdog is investigating Bi Jingquan, the former head of the China Food and Drug Administration. Daiichi Sankyo, along with partner Merck & Co., pulled an FDA approval filing for an antibody-drug conjugate cancer prospect. Novartis expanded a commercial collaboration with Shanghai Pharma. Plus more.

May 30, 2025 - 12:10
 0
Fierce Pharma Asia—Former China FDA head under investigation; Daiichi pulls ADC filing
China's anti-graft watchdog is investigating Bi Jingquan, the former head of the China Food and Drug Administration. Daiichi Sankyo, along with partner Merck & Co., pulled an FDA approval filing for an antibody-drug conjugate cancer prospect. Novartis expanded a commercial collaboration with Shanghai Pharma. Plus more.
Read More

Tags:

Previous Article

Sandicliffe celebrated again among best companies by The Times

Next Article

The opportunity in China’s solar ‘overcapacity’

Related Posts

Mayne hit by 'misleading' drug safety claims from the FDA ahead of $430M buyout

Mayne hit by 'misleading' drug safety claims from the F...

May 13, 2025  0

J&J's Darzalex wins FDA advisors' backing as potential first treatment for smoldering myeloma

J&J's Darzalex wins FDA advisors' backing as potential ...

May 21, 2025  0

Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease

Alcon gains first FDA prescription drug nod since Novar...

May 29, 2025  0